Search research articles
Contact Us
Filters
Showing results (141-150 of 420) with videos related to
Page
of 42
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
December 13, 2005
Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent
R Stokes Peebles, Koichi Hashimoto, James R Sheller, et al.
Vaccine
|
February 10, 2023
A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques
Alberto Peretti, Diana G Scorpio, Wing-Pui Kong, et al.
Journal of Virology
|
July 10, 2015
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate
Bo Liang, Sonja Surman, Emerito Amaro-Carambot, et al.
Plos Pathogens
|
July 3, 2013
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1
Tomer Hertz, Hasan Ahmed, David P Friedrich, et al.
Science Translational Medicine
|
December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
Lauren A Chang, Emily Phung, Michelle C Crank, et al.
AIDS Research and Human Retroviruses
|
May 27, 2014
The immune space: a concept and template for rationalizing vaccine development
Amapola Manrique, Elizabeth Adams, Dan H Barouch, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 8, 2004
Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5
Koichi Hashimoto, Barney S Graham, Samuel B Ho, et al.
Virology
|
March 21, 2009
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination
Katie L Davis, Elin S Gray, Penny L Moore, et al.
Plos One
|
March 14, 2014
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
Mary E Enama, Julie E Ledgerwood, Laura Novik, et al.
Journal of Virology
|
June 10, 2016
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats
Christina A Rostad, Christopher C Stobart, Brian E Gilbert, et al.
Page
of 42
Search research articles
Search
Showing results (141-150 of 420) with videos related to
Sort By:
Page
of 42
Journal of Immunology (Baltimore, Md. : 1950)
|
December 13, 2005
Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent
R Stokes Peebles, Koichi Hashimoto, James R Sheller, et al.
Vaccine
|
February 10, 2023
A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques
Alberto Peretti, Diana G Scorpio, Wing-Pui Kong, et al.
Journal of Virology
|
July 10, 2015
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate
Bo Liang, Sonja Surman, Emerito Amaro-Carambot, et al.
Plos Pathogens
|
July 3, 2013
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1
Tomer Hertz, Hasan Ahmed, David P Friedrich, et al.
Science Translational Medicine
|
December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine
Lauren A Chang, Emily Phung, Michelle C Crank, et al.
AIDS Research and Human Retroviruses
|
May 27, 2014
The immune space: a concept and template for rationalizing vaccine development
Amapola Manrique, Elizabeth Adams, Dan H Barouch, et al.
American Journal of Respiratory and Critical Care Medicine
|
May 8, 2004
Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5
Koichi Hashimoto, Barney S Graham, Samuel B Ho, et al.
Virology
|
March 21, 2009
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination
Katie L Davis, Elin S Gray, Penny L Moore, et al.
Plos One
|
March 14, 2014
Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
Mary E Enama, Julie E Ledgerwood, Laura Novik, et al.
Journal of Virology
|
June 10, 2016
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats
Christina A Rostad, Christopher C Stobart, Brian E Gilbert, et al.
Page
of 42